Syros Gets ‘Tyme’ To Bring Lead Candidate To Pivotal Readout

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Gene-expression focused Syros adds about $190m to its coffers with Tyme merger and PIPE financing. This will get it past pivotal data for tamibarotene and enable Phase III development of a leukemia candidate.

Sand running through the bulbs of an hourglass measuring the passing time in a countdown to a deadline, on a dark background with copy space.
Time was a primary obstacle for Syros, until it agreed to merge with Tyme

Syros Pharmaceuticals, Inc. significantly extended its financial runway through three concurrent transactions on 5 July that are expected to fund company operations into 2025 and get it well past the expected readout of pivotal Phase III data for its lead candidate tamibarotene in higher-risk myelodysplastic syndrome (HR-MDS) patients. In the process, Syros will merge with Tyme Technologies, Inc., acquiring about $60m in cash and that company’s stalled cancer metabolism-based therapy SM-88.

Both companies’ boards of directors have agreed to the proposed all-stock merger of Syros and Tyme, expected to close during...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.